Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark), today announced the launch of RYALTRIS Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older.
Market Samachar is a news aggregator. This article was originally published by Share Market Today. Tap the button above to read the full story on their site.